TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · see citing works

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368 · see citing works

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955 · see citing works

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338 · see citing works

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730 · see citing works

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial

Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517 · see citing works

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426 · see citing works

Cancer burden in the year 2000. The global picture

Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169 · see citing works

DECLARATION OF HELSINKI.

Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,068 · see citing works

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,703 · see citing works

Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

Kelly, K. L., Crowley, J. J., Bunn, P. A., Presant, C. A., Grevstad, P. K., Moinpour, C. M., Ramsey, S. D., Wozniak, A. J., Weiss, G. R., Moore, D. F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3210 · Cited by 1,122 · see citing works

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Perez-Soler, R., Chachoua, A., Hammond, L. A., Rowinsky, E. K., Huberman, M. S., Karp, D. D., Rigas, J. R., Clark, G. M., Santabarbara, P., & Bonomi, P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.057 · Cited by 1,067 · see citing works

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001 · see citing works

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Soulieres, D., Senzer, N. N., Vokes, E. E., Hidalgo, M., Agarwala, S. S., & Siu, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.075 · Cited by 807 · see citing works

Corrigendum to “Cancer burden in the year 2000. The global picture” [European Journal of Cancer,37(Suppl. 8) (2001) S4–S66]

Parkin, D. M., Bray, F., & Devesa, S. S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00739-6 · Cited by 479 · see citing works

Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆☆☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.

Evans, W. K. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.08.002 · Cited by 405 · see citing works

Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255

Tracy, S. I., Mukohara, T., Hansen, M., Meyerson, M. M., Johnson, B. E., & Janne, P. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1905 · Cited by 368 · see citing works

A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial

Shepherd, F. A., Pereira, J. R., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Bezjak, A., Tu, D., Santabarbara, P., & Seymour, L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7022 · Cited by 281 · see citing works

Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers.

Sánchez‐Céspedes, M., Ahrendt, S. A., Piantadosi, S., Rosell, R., Monzó, M., Wu, L., Westra, W. H., Yang, S. C., Jen, J., & Sidransky, D. (2001) · PubMed · Cited by 169 · see citing works

Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical Trials

Betensky, R. A., Louis, D. N., & Cairncross, J. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.140 · Cited by 166 · see citing works

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

Higgins, B., Kolinsky, K. D., Smith, M. L., Beck, G., Rashed, M., Adames, V., Linn, M., Wheeldon, E. B., Gand, L., Birnboeck, H., et al. (2004) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000127664.66472.60 · Cited by 152 · see citing works

Novel Agents in the Treatment of Lung Cancer

Lynch, T. J., Adjei, A. A., Bunn, P. A., DuBois, R. N., Gandara, D. R., Giaccone, G., Govindan, R., Herbst, R. S., Johnson, B. E., Khuri, F. R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040021 · Cited by 24 · see citing works

HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial

Perez, E. A., Suman, V. J., Davidson, N. E., Martino, S., Kaufman, P. A., Lingle, W. L., Flynn, P. J., Ingle, J. N., Visscher, D. W., & Jenkins, R. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.567 · Cited by 20 · see citing works

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC)

Tran, H. T., Zinner, R., Blumenschein, G. R., Oh, Y. W., Papadimitrakopoulou, V. A., Kim, E. S., Lu, C. S., Malik, M., Lum, B. L., & Herbst, R. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.2050 · Cited by 2 · see citing works

Epithelial-Mesenchymal Transitions in Development and Disease

Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931 · see citing works

EGFR Antagonists in Cancer Treatment

Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,063 · see citing works

Lung cancer in never smokers — a different disease

Sun, S., Schiller, J. H., & Gazdar, A. F. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2190 · Cited by 1,601 · see citing works

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,453 · see citing works

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Pirker, R., Pereira, J. R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Vynnychenko, I. O., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,346 · see citing works

Toward personalized treatment approaches for non-small-cell lung cancer

Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,113 · see citing works

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083 · see citing works

Role of Tyrosine Kinase Inhibitors in Cancer Therapy

Arora, A., & Scholar, E. M. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,016 · see citing works

Lung cancer in never smokers – A review

Couraud, S., Zalcman, G., Milleron, B. J., Morin, F., & Souquet, P.-J. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.007 · Cited by 962 · see citing works

Targeting the EGFR signaling pathway in cancer therapy

Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.648617 · Cited by 920 · see citing works

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915 · see citing works

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Rosa, F. D., Milanowski, J., Karnicka-Mlodkowski, H., Pešek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 875 · see citing works

Cell death-based treatment of lung adenocarcinoma

Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018) · Cell Death &amp; Disease · doi:10.1038/s41419-017-0063-y · Cited by 768 · see citing works

Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer

Baselga, J. M., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 721 · see citing works

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

Hirsch, F. R., Varella-Garcia, M., Bunn, P. A., Franklin, W. A., Dziadziuszko, R., Thatcher, N., Chang, A., Parikh, P., Pereira, J. R., Ciuleanu, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3958 · Cited by 703 · see citing works

Lung Cancer in Never Smokers: A Review

Subramanian, J., & Govindan, R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8015 · Cited by 705 · see citing works

Epidermal Growth Factor Receptor Targeting in Cancer

Mendelsohn, J. M., & Baselga, J. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693 · see citing works

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Wheeler, D. L., Dunn, E. F., & Harari, P. M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.97 · Cited by 683 · see citing works

Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions

Pao, W. J., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 628 · see citing works

Mechanisms of resistance to cisplatin and carboplatin

Stewart, D. J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.02.001 · Cited by 631 · see citing works

Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer

Sequist, L. V. D., Bell, D. W., Lynch, T. J., & Haber, D. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3585 · Cited by 617 · see citing works

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

Bell, D. W., Lynch, T. J., Haserlat, S. M., Harris, P. L., Okimoto, R. A., Brannigan, B. W., Sgroi, D. C., Muir, B., Riemenschneider, M. J., Iacona, R. B., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7078 · Cited by 598 · see citing works

Overcoming therapy resistance in EGFR-mutant lung cancer

Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565 · see citing works

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4824 · Cited by 573 · see citing works

Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study

Hirsch, F. R., Varella‐Garcia, M., McCoy, J., West, H., Xavier, A. C., Gumerlock, P. H., Bunn, P. A., Franklin, W. A., Crowley, J. J., & Gandara, D. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.2823 · Cited by 570 · see citing works

Antibody Therapeutics in Cancer

Sliwkowski, M. X., & Mellman, I. (2013) · Science · doi:10.1126/science.1241145 · Cited by 543 · see citing works

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

Siena, S., Bianchi, A. S., Nicolantonio, F. D., Balfour, J., & Bardelli, A. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp280 · Cited by 526 · see citing works

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

Lee, C. K., Brown, C. S. B., Gralla, R. J., Hirsh, V., Thongprasert, S., Tsai, C., Tan, E. H., Ho, J., Chu, D., Zaatar, A., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt072 · Cited by 505 · see citing works

Epithelial versus Mesenchymal Phenotype Determines <i>In vitro</i> Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Yauch, R. L., Januario, T., Eberhard, D. A., Cavet, G., Zhu, W., Fu, L., Pham, T. Q., Soriano, R., Stinson, J., Seshagiri, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1492 · Cited by 495 · see citing works

Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?

Perez-Soler, R., & Saltz, L. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.6916 · Cited by 485 · see citing works

Mechanisms of resistance to EGFR-targeted drugs: lung cancer

Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000060 · Cited by 476 · see citing works

Angiogenesis Inhibitors: Current Strategies and Future Prospects

Cook, K. M., & Figg, W. D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20075 · Cited by 478 · see citing works

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

Lynch, T. J., Patel, T., Dreisbach, L., McCleod, M., Heim, W. J., Hermann, R. C., Paschold, E., Iannotti, N. O., Dakhil, S., Gorton, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9618 · Cited by 447 · see citing works

FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets

Cohen, M. H., Johnson, J. R., Chen, Y., Sridhara, R., & Pazdur, R. (2005) · The Oncologist · doi:10.1634/theoncologist.10-7-461 · Cited by 447 · see citing works

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

Scagliotti, G. V., Novello, S., von Pawel, J., Reck, M., Pereira, J. R., Thomas, M., Miziara, J. E., Bálint, B., de Marinis, F., Keller, A. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1321 · Cited by 446 · see citing works

Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib

Carey, K. D., Garton, A. J., Romero, M. S., Kahler, J., Thomson, S., Ross, S., Park, F., Haley, J. D., Gibson, N., & Sliwkowski, M. X. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0453 · Cited by 445 · see citing works

Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer

Butts, C. A., Murray, N., Maksymiuk, A. W., Goss, G. D., Marshall, E., Soulières, D., Cormier, Y. F., Ellis, P., Price, A., Sawhney, R. P. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.011 · Cited by 427 · see citing works

Epidermal growth factor receptor inhibition strategies in oncology

Harari, P. M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00600 · Cited by 423 · see citing works

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

Cataldo, V. D., Gibbons, D. L., Perez-Soler, R., & Quintás‐Cardama, A. (2011) · New England Journal of Medicine · doi:10.1056/nejmct0807960 · Cited by 422 · see citing works

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer

Noronha, V., Patil, V., Joshi, A., Menon, N. S., Chougule, A., Mahajan, A., Janu, A., Purandare, N. C., Kumar, R., More, S. B., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01154 · Cited by 420 · see citing works

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

Herbst, R. S., Sun, Y. P., Eberhardt, W., Germonpré, P. R., Saijo, N., Zhou, C., Wang, J., Li, L., Kabbinavar, F. F., Ichinose, Y., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70132-7 · Cited by 414 · see citing works

Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology

Janne, P. A., Engelman, J. A., & Johnson, B. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.985 · Cited by 405 · see citing works

Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer

Fennell, D. A., Summers, Y., Cadranel, J. L., Benepal, T., Christoph, D. C., Lal, R., Das, M., Maxwell, F., Visseren‐Grul, C., & Ferry, D. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.01.003 · Cited by 382 · see citing works

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Patel, J. D., Socinski, M. A., Garon, E. B., Reynolds, C. H., Spigel, D. R., Olsen, M. R., Hermann, R. C., Jotte, R. M., Beck, T., Richards, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.9626 · Cited by 369 · see citing works

Strategies for optimizing combinations of molecularly targeted anticancer agents

Dancey, J. E., & Chen, H. X. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2089 · Cited by 368 · see citing works

Prognostic versus predictive value of biomarkers in oncology

Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A., & de Vries, E. G. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.006 · Cited by 349 · see citing works

A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies

Schaefer, G., Haber, L., Crocker, L., Shia, S., Shao, L., Dowbenko, D. J., Tótpál, K., Wong, A., Lee, C. V., Stawicki, S. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341 · see citing works

Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions

Ramalingam, S. S., & Belani, C. P. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s1-5 · Cited by 333 · see citing works

ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine

Ceppi, P., Volante, M., Novello, S., Rapa, I., Danenberg, K. D., Danenberg, P. V., Cambieri, A., Selvaggi, G., Saviozzi, S., Calogero, R., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl300 · Cited by 321 · see citing works

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

Thomas, M. B., Chadha, R., Glover, K. Y., Wang, X., Morris, J. S., Brown, T. D., Rashid, A., Dancey, J. E., & Abbruzzese, J. L. (2007) · Cancer · doi:10.1002/cncr.22886 · Cited by 305 · see citing works

Integration of EGFR inhibitors with radiochemotherapy

Nyati, M. K., Morgan, M. A., Feng, F. Y.-C., & Lawrence, T. S. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1953 · Cited by 302 · see citing works

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting

Eberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 300 · see citing works

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

Wu, Y.-L. L. C., Lee, J. S., Thongprasert, S., Yu, C., Zhang, L., Ladrera, G., Srimuninnimit, V., Sriuranpong, V., Sandoval-Tan, J., Zhu, Y., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70254-7 · Cited by 298 · see citing works

Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

Heymach, J. V., Johnson, B. E., Prager, D., Csada, E., Roubec, J., Pešek, M., Špásová, I., Belani, C. P., Bodrogi, I., Gadgeel, S. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5122 · Cited by 292 · see citing works

Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer

Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., & Han, W. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5023-8 · Cited by 290 · see citing works

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

Boer, R. H. D., Arrieta, O. G., Yang, C.-H., Gottfried, M., Chan, V. F., Raats, J., de Marinis, F., Abratt, R. P., Wolf, J., Blackhall, F. H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5717 · Cited by 287 · see citing works

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

Asahina, H., Yamazaki, K., Kinoshita, I., Sukoh, N., Harada, M., Yokouchi, H., Ishida, T., Ogura, S., Kojima, T., Okamoto, Y., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603393 · Cited by 276 · see citing works

KRAS: From undruggable to a druggable Cancer Target

Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102070 · Cited by 271 · see citing works

EGFR Targeting of Solid Tumors

Rocha‐Lima, C., Soares, H. P., Raez, L. E., & Singal, R. (2007) · Cancer Control · doi:10.1177/107327480701400313 · Cited by 275 · see citing works

Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges

Rodríguez, F., Caruana, P., de la Fuente, N., Español, P., Gámez, M., Balart, J., Llurba, E., Rovira, R., Ruiz, R., Martín-Lorente, C., et al. (2022) · Biomolecules · doi:10.3390/biom12060784 · Cited by 281 · see citing works

A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320

Sperduto, P. W., Wang, M., Robins, H. I., Schell, M. C., Werner-Wasik, M., Komaki, R., Souhami, L., Buyyounouski, M. K., Khuntia, D., Demas, W., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.11.042 · Cited by 274 · see citing works

Smoking at diagnosis and survival in cancer patients

Warren, G. W., Kasza, K. A., Reid, M. E., Cummings, K. M., & Marshall, J. R. (2013) · International Journal of Cancer · doi:10.1002/ijc.27617 · Cited by 265 · see citing works

Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy

Hirsch, F. R., Herbst, R. S., Olsen, C. C., Chansky, K., Crowley, J. J., Kelly, K. L., Franklin, W. A., Bunn, P. A., Varella‐Garcia, M., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0111 · Cited by 271 · see citing works

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib

Hirsch, F. R., Varella‐Garcia, M., Cappuzzo, F., McCoy, J., Bemis, L., Xavier, A. C., Dziadziuszko, R., Gumerlock, P. H., Chansky, K., West, H., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm003 · Cited by 266 · see citing works

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Rosell, R., Robinet, G., Szczęsna, A., Ramlau, R., Constenla, M., Mennecier, B., Pfeifer, W., O'Byrne, K. J., Welte, T., Kolb, R., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm474 · Cited by 258 · see citing works

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy

Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255 · see citing works

Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib

Taniguchi, K., Okami, J., Kodama, K., Higashiyama, M., & Kato, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00782.x · Cited by 251 · see citing works

Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors

Vahid, B., & Marik, P. E. (2008) · CHEST Journal · doi:10.1378/chest.07-0851 · Cited by 254 · see citing works

Targeted therapy in non-small-cell lung cancer—is it becoming a reality?

Jankú, F., Stewart, D. J., & Kurzrock, R. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.64 · Cited by 252 · see citing works

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

Greenhalgh, J., Dwan, K. M., Boland, A., Bates, V., Vecchio, F., Dundar, Y., Jain, P., & Green, J. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010383.pub2 · Cited by 244 · see citing works

Therapeutic management options for stage III non-small cell lung cancer

Yoon, S. M., Shaikh, T., & Hallman, M. A. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i1.1 · Cited by 245 · see citing works

Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative

Molinolo, A. A., Hewitt, S. M., Amornphimoltham, P., Keelawat, S., Rangdaeng, S., Meneses García, A., Raimondi, A. R., Jufe, R., Itoiz, M., Gao, Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1041 · Cited by 243 · see citing works

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Janne, P. A., Wang, X., Socinski, M. A., Crawford, J., Stinchcombe, T. E., Gu, L., Capelletti, M., Edelman, M. J., Villalona-Calero, M. A., Kratzke, R. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1315 · Cited by 241 · see citing works

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

Gridelli, C., Ciardiello, F., Gallo, C., Feld, R. D., Butts, C. A., Gebbia, V., Maione, P., Morgillo, F., Genestreti, G., Favaretto, A. G., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2056 · Cited by 235 · see citing works

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

Linardou, H., Dahabreh, I. J., Bafaloukos, D. I., Kosmidis, P., & Murray, S. J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.62 · Cited by 234 · see citing works

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non–small cell lung cancer

Lü, J., Eppler, S., WOLF, J., Hamilton, M., Rakhit, A. K., Bruno, R., & Lum, B. L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.04.007 · Cited by 223 · see citing works

Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor SurvivalIn vivoin Non–Small Cell Lung Cancer

Haura, E. B., Zheng, Z., Song, L., Cantor, A. B., & Bepler, G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0827 · Cited by 224 · see citing works

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Heymach, J. V., Paz-Ares, L. G., de Braud, F., Sebastian, M., Stewart, D. J., Eberhardt, W., Ranade, A. A., Cohen, G. L., Trigo, J. M., Sandler, A. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3138 · Cited by 221 · see citing works

ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

Gerber, D. E., & Minna, J. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.033 · Cited by 220 · see citing works

EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan

Takano, T., Fukui, T., Ohe, Y., Tsuta, K., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Furuta, K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7254 · Cited by 220 · see citing works

Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma1

Prados, M. D., Lamborn, K. R., Chang, S. M., Burton, E. M., Butowski, N. A., Malec, M. K., Kapadia, A., Rabbitt, J. E., Page, M. S., Fedoroff, A., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000451 · Cited by 217 · see citing works

Biological and clinical implications of EGFR mutations in lung cancer

Mitsudomi, T., Kosaka, T., & Yatabe, Y. (2006) · International Journal of Clinical Oncology · doi:10.1007/s10147-006-0583-4 · Cited by 216 · see citing works

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Reslan, H. B., Ho, C., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 215 · see citing works

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Mok, T. S. K., Wu, Y.-L. L. C., Yu, C., Zhou, C., Chen, Y.-M., Zhang, L., Ignacio, J. G., Liao, M., Srimuninnimit, V., Boyer, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.5541 · Cited by 215 · see citing works

Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer Cells

Li, T., Ling, Y., Goldman, I. D., & Perez-Soler, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2923 · Cited by 214 · see citing works

Biology of Interactions: Antiepidermal Growth Factor Receptor Agents

Harari, P. M., Allen, G. W., & Bonner, J. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8984 · Cited by 214 · see citing works

Molecular predictive and prognostic markers in non-small-cell lung cancer

Coate, L. E., John, T., Tsao, M., & Shepherd, F. A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70155-x · Cited by 214 · see citing works

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

Cappuzzo, F., Ligorio, C., Janne, P. A., Toschi, L., Rossi, E., Trisolini, R., Paioli, D., Tisch, A. H., Magrini, E., Finocchiaro, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4300 · Cited by 210 · see citing works

Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

Argiris, A. E., Ghebremichael, M. S., Gilbert, J., Lee, J., Sachidanandam, K., Kolesar, J., Burtness, B. A., & Forastiere, A. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.4272 · Cited by 210 · see citing works

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

Peereboom, D. M., Shepard, D. R., Ahluwalia, M. S., Brewer, C. J., Agarwal, N., Stevens, G. H. J., Suh, J. H., Toms, S. A., Vogelbaum, M. A., Weil, R. J., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0067-2 · Cited by 205 · see citing works

Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non–Small-Cell Lung Cancer

Giaccone, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.409 · Cited by 204 · see citing works

Multicenter Phase I/II Study of Cetuximab With Paclitaxel and Carboplatin in Untreated Patients With Stage IV Non–Small-Cell Lung Cancer

Thienelt, C. D., Bunn, P. A., Hanna, N. H., Rosenberg, A., Needle, M. N., Long, M. E., Gustafson, D. L., & Kelly, K. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1997 · Cited by 203 · see citing works

Individual patient data analysis to assess modifications to the RECIST criteria.

Bogaerts, J., Ford, R., Sargent, D., Schwartz, L., Rubinstein, L., Lacombe, D., Eisenhauer, E., Verweij, J., & Therasse, P. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.027 · Cited by 201 · see citing works

Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study

Giaccone, G., Ruiz, M. I. G., Chevalier, T. L., Thatcher, N., Smit, E. F., Rodríguez, J. A., Janne, P. A., Oulid-Aïssa, D., & Soria, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0260 · Cited by 199 · see citing works

New molecularly targeted therapies for lung cancer

Sun, S., Schiller, J. H., Spinola, M., & Minna, J. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31809 · Cited by 201 · see citing works

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions

Barr, S. M., Thomson, S., Buck, E. A., Russo, S. M., Petti, F., Sujka-Kwok, I., Eyzaguirre, A., Rosenfeld-Franklin, M., Gibson, N. W., Miglarese, M. R., et al. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9121-7 · Cited by 197 · see citing works

Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer

Butts, C. A., Bodkin, D., Middleman, E. L., Englund, C. W., Ellison, D. H., Alam, Y., Kreisman, H., Graze, P. R., Maher, J. F., Ross, H. J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0856 · Cited by 194 · see citing works

Smoking, The Missing Drug Interaction in Clinical Trials: Ignoring the Obvious

Gritz, E. R., Dresler, C. M., & Sarna, L. P. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0224 · Cited by 192 · see citing works

First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review

Goffin, J. R., Lacchetti, C., Ellis, P. M., Ung, Y., & Evans, W. K. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181c6f035 · Cited by 191 · see citing works

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition

Buck, E. A., Eyzaguirre, A., Barr, S. M., Thompson, S. D., Sennello, R., Young, D., Iwata, K. K., Gibson, N. W., Cagnoni, P. J., & Haley, J. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0462 · Cited by 191 · see citing works

Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial

Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Rosa, F. D., Milanowski, J., Karnicka-Mlodkowski, H., Pešek, M., Serwatowski, P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1474 · Cited by 875 · see citing works

Beyond the Tribute Trial: Integrating Her1/Egfr Tyrosine Kinase Inhibitors With Chemotherapy In Advanced Nsclc

Reck, M. (2006) · Future Oncology · doi:10.2217/14796694.2.1.47 · Cited by 9 · see citing works

Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE

Miller, V. A., Herbst, R. S., Prager, D., Fehrenbacher, L., Hermann, R., Hoffman, P. C., Johnson, B. E., Sandler, A. B., Kris, M. G., & Ramies, D. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.7061 · Cited by 51 · see citing works

Select Clinical Trials of Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer with Emphasis on Phase III Outcomes

Fuster, L. M. B., & Sandler, A. B. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.s.011 · Cited by 46 · see citing works

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

Gatzemeier, U., Pluzanska, A., Szczęsna, A., Kaukel, E., Roubec, J., Brennscheidt, U., Rosa, F. D., Mueller, B., & von Pawel, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7010 · Cited by 311 · see citing works